Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Learn where to sell items for fast cash and declutter your space. Get quick cash for your unwanted belongings.
20,471 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Five years into Andy Jassy’s tenure, a $10,000 investment in Amazon would be worth about $13,500, a gain that trails ...
Warren Buffett publicly stated he initiated Berkshire Hathaway’s larger stake in Alphabet, signaling a top-down push ...
Copper futures tumbled intraday as supply climbs and demand questions linger. The move pins attention on five NYSE-li...
Garmin delivered a dominant Q4 with a big EPS beat and revenue surge, triggering a sharp market rally as investors we...
As AI and data demand surge, investors eye NuScale Power and the small modular reactor trend. Can nuscale power next ...
When a smart-home name rallies, traders pay attention. This piece breaks down why resideo technologies stock popped o...
Is Nike losing its spark in performance running? This article dives into whether nike lost edge performance and what ...
Think HSAs are only for medical bills? This guide reveals how to leverage an HSA as a stealth retirement account—comb...
Biotech stocks rally as late-stage trial data and regulatory milestones boost investor confidence. Analysts say the b...
In a volatile start to 2026, investors are seeking dividend ETFs built survive strategies that combine durable income...
Bitcoin traders grapple with a tightening macro backdrop as the Fed's liquidity cushion shrinks, signaling tighter fu...